Inhibition of angiotensin II action protects rat steatotic livers against ischemia-reperfusion injury

被引:43
|
作者
Casillas-Ramirez, Arani [1 ]
Amine-Zaouali, Mohammed [2 ]
Massip-Salcedo, Marta [1 ,5 ]
Padrissa-Altes, Susagna [2 ]
Bintanel-Morcillo, Maria
Ramalho, Fernando [2 ]
Serafin, Anna [3 ]
Rimola, Antoni [4 ,5 ]
Arroyo, Vicente [4 ,5 ]
Rodes, Juan [4 ,5 ]
Rosello-Catafau, Joan [2 ,5 ]
Peralta, Carmen [1 ]
机构
[1] Consejo Super Investigac Cient, Inst Investigac Biomed August Pi & Sunyer, Unitat Transplantament Fetge & Viabilitat Empelt, Barcelona, Spain
[2] Consejo Super Investigac Cient, Inst Investigac Biomed Barcelona, Expt Hepat Ischemia Reperfus Unit, Barcelona, Spain
[3] Univ Autonoma Barcelona, Fac Vet, Dept Anim Med & Surg, E-08193 Barcelona, Spain
[4] Hosp Clin Univ, Inst Investigac Biomed August Pi & Sunyer, Dept Liver Unit, Barcelona, Spain
[5] CIBER, EHD, Inst Salud Carlos III, IDIBAPS, Barcelona, Spain
关键词
steatotic liver; angiotensin II; bradykinin; interleukin; ischemia; ischemic preconditioning;
D O I
10.1097/CCM.0b013e31816a023c
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objective: We examined whether pharmacologic strategies blocking angiotensin II actions protect steatotic livers against ischemia-reperfusion (I/R) injury. The effects of ischemic preconditioning (PC) on angiotensin II were also evaluated. Design: Randomized and controlled animal study. Setting: Experimental laboratory. Subjects: Zucker rats. Interventions: The following experimental groups were studied: I/R, ischemia-reperfusion + angiotensin-converting enzyme inhibitor (I/R+ACE inhibitor), ischemia-reperfusion + angiotensin II type I receptor antagonist (I/R+AT1R antagonist), ischemia-reperfusion + angiotensin 11 type 11 receptor antagonist (I/R+AT2R antagonist), and PC (5 mins of ischemia + 10 mins of reperfusion before I/R). In some of these groups, the action of bradykinin (BK) and/or peroxisome-proliferator-activated receptor-gamma (PPAR-gamma) was altered pharmacologically. Measurements and Main Results. I/R+ACE inhibitor, I/R+AT1R antagonist, and I/R+AT2R antagonist reduced hepatic injury in steatotic livers compared with the I/R group. PC reduced angiotensin II generation and hepatic injury in steatotic livers in comparison to I/R group. Our results revealed that I/R+ACE inhibitor, I/R+AT1R antagonist, I/R+AT2R antagonist, and PC increased BK compared with the I/R group. In addition, the effects of PC on BK and hepatic injury were abolished when angiotensin 11 was administered. Furthermore, administration of BK receptor antagonists to the I/R+ACE inhibitor, I/R+AT1R antagonist, I/R+AT2R antagonist, and PC groups resulted in hepatic injury similar to the I/R group, indicating that the benefits of ACE inhibitor, AT1R antagonist, AT2R antagonist, and PC were abolished when the action of BK was inhibited. Experiments aimed at investigating why BK was protective in steatotic livers indicated that BK acts as a positive regulator of PPAR-gamma. If PPAR gamma action was inhibited, BK did not protect steatotic livers against hepatic injury. Conclusions. Pharmacologic blockers of angiotensin II action (ACE inhibitors, AT1R antagonists, and AT2R antagonists) and PC, which reduced angiotensin II generation, increased BK generation in steatotic livers after I/R. This in turn increased PPAR gamma and protected this type of liver against I/R injury.
引用
收藏
页码:1256 / 1266
页数:11
相关论文
共 50 条
  • [21] The use of the papworth cocktail is detrimental to steatotic livers after ischemia-reperfusion injury
    Ellett, Justin D.
    Evans, Zachary P.
    Fiorini, Jennifer H.
    Fiorini, Ryan N.
    Haines, Julia K.
    Schmidt, Michael G.
    Chavin, Kenneth D.
    TRANSPLANTATION, 2008, 86 (02) : 286 - 292
  • [22] Heat shock preconditioning ameliorates liver injury following normothermic ischemia-reperfusion in steatotic rat livers
    Yamagami, K
    Yamamoto, Y
    Kume, M
    Kimoto, S
    Yamamoto, H
    Ozaki, N
    Yamamoto, M
    Shimahara, Y
    Toyokuni, S
    Yamaoka, Y
    JOURNAL OF SURGICAL RESEARCH, 1998, 79 (01) : 47 - 53
  • [23] Intermedin protects against renal ischemia-reperfusion injury by inhibition of oxidative stress
    Qiao, Xi
    Li, Rong-Shan
    Li, Hong
    Zhu, Guo-Zhen
    Huang, Xiao-Guang
    Shao, Shan
    Bai, Bo
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2013, 304 (01) : F112 - F119
  • [24] CaMKII inhibition protects against necrosis and apoptosis in irreversible ischemia-reperfusion injury
    Vila-Petroff, Martin
    Salas, Margarita A.
    Said, Matilde
    Valverde, Carlos A.
    Sapia, Luciana
    Portiansky, Enrique
    Hajjar, Roger J.
    Kranias, Evangelia G.
    Mundina-Weilenmann, Cecilia
    Mattiazzi, Alicia
    CARDIOVASCULAR RESEARCH, 2007, 73 (04) : 689 - 698
  • [25] Biliverdin protects rat livers from ischemia/reperfusion injury
    Fondevila, C
    Katori, M
    Lassman, C
    Carmody, I
    Busuttil, RW
    Bach, FH
    Kupiec-Weglinski, JW
    TRANSPLANTATION PROCEEDINGS, 2003, 35 (05) : 1798 - 1799
  • [26] Targeting Ninjurin-1 protects mice and rat livers from ischemia-reperfusion injury
    Mossemann, J.
    Martins, B.
    Zhao, S.
    Ali, D.
    Bilan, P.
    Steinberg, B.
    Sayed, B.
    LIVER TRANSPLANTATION, 2024, 30 : 256 - 257
  • [27] Icariin protects against intestinal ischemia-reperfusion injury
    Zhang, Feng
    Hu, Yan
    Xu, Xiaomei
    Zhai, Xiaohan
    Wang, Guangzhi
    Ning, Shili
    Yao, Jihong
    Tian, Xiaofeng
    JOURNAL OF SURGICAL RESEARCH, 2015, 194 (01) : 127 - 138
  • [28] Erythropoietin protects the heart against ischemia-reperfusion injury
    Van der Meer, P
    Lipsic, E
    Henning, RH
    De Boer, RA
    Suurmeijer, AJ
    Van Veldhuisen, DJ
    Van Gilst, WH
    CIRCULATION, 2003, 108 (17) : 187 - 188
  • [29] Sevoflurane postconditioning protects isolated rat hearts against ischemia-reperfusion injury
    Yao Yun-tai
    Fang Neng-xin
    Shi Chun-xia
    Li Li-huan
    CHINESE MEDICAL JOURNAL, 2010, 123 (10) : 1320 - 1328
  • [30] Vinpocetine protects liver against ischemia-reperfusion injury
    Zaki, Hala Fahmy
    Abdelsalam, Rania Mohsen
    CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2013, 91 (12) : 1064 - 1070